Antibiotics · 2022 · 13 citations · 21 references
Veterinary MedicineInfectious DiseasesMicrobiologyAntimicrobial ResistanceDiagnostic MicrobiologyMedical MicrobiologyAntibiotic ResistanceAntimicrobial Susceptibility TestingPathogen DetectionVolatile Substance AnalysisAntibacterial Susceptibility TestingAntibiotic Sensitivity TestingAntibiotic Susceptibility TestingDirect From Blood DiagnosticsMicrobial Susceptibility TestingMicrobial Volatile Organic CompoundsMinimum Inhibitory Concentration TestingVolatile Organic Compound Detection
Background: Bacteria produce volatile organic compounds (VOCs) during growth, which can be detected by colorimetric sensor arrays (CSAs). The SpecifAST® system (Specific Diagnostics) employs this technique to enable antibiotic susceptibility testing (AST) directly from blood cultures without prior subculture of isolates. The aim of this study was to compare the SpecifAST® AST results and analysis time to the VITEK®2 (bioMérieux) system. Methods: In a 12-month single site prospective study, remnants of clinical positive monomicrobial blood cultures were combined with a series of antibiotic concentrations. Volatile emission was monitored at 37 °C via CSAs. Minimal Inhibitory Concentrations (MICs) of seven antimicrobial agents for Enterobacterales, Staphylococcus, and Enterococcus spp. were compared to VITEK®2 AST results. MICs were interpreted according to EUCAST clinical breakpoints. Performance was assessed by calculating agreement and discrepancy rates. Results: In total, 96 positive blood cultures containing Enterobacterales, Staphylococcus, and Enterococcus spp. were tested (269 bug–drug combinations). The categorical agreement of the SpecifAST® system compared to the VITEK®2 system was 100% and 91% for Gram-negatives and Gram-positives, respectively. Errors among Gram-positives were from coagulase-negative staphylococci. Overall results were available in 3.1 h (±0.9 h) after growth detection without the need for subculture steps. Conclusion: The AST results based on VOC detection are promising and warrant further evaluation in studies with a larger sample of bacterial species and antimicrobials.
21
Matthias Marschal, Johanna Bachmaier, Ingo B. Autenrieth et al. · Journal of Clinical Microbiology · 2017 · 166 citations · Full text
Angella Charnot‐Katsikas, Vera Tešić, Nedra Love et al. · Journal of Clinical Microbiology · 2017 · 166 citations · Full text
Agnes W. Boots, Agnieszka Smolinska, Joep J B N van Berkel et al. · Journal of Breath Research · 2014 · 153 citations